Swiss National Bank increased its position in shares of Celgene Co. (NASDAQ:CELG) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,333,996 shares of the biopharmaceutical company’s stock after buying an additional 47,400 shares during the period. Swiss National Bank owned 0.33% of Celgene worth $220,189,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Bruderman Asset Management LLC acquired a new position in shares of Celgene in the fourth quarter valued at $25,000. Murphy Pohlad Asset Management LLC acquired a new position in shares of Celgene in the fourth quarter valued at $25,000. Athena Capital Advisors LLC bought a new stake in shares of Celgene in the fourth quarter valued at about $27,000. Investors Research Corp bought a new stake in shares of Celgene in the first quarter valued at about $28,000. Finally, Liberty Wealth Management LLC bought a new stake in shares of Celgene in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 75.00% of the company’s stock.
A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Saturday, May 4th. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Barclays cut shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a research report on Friday, May 3rd. Atlantic Securities cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price for the company. in a research report on Monday, April 1st. Finally, Mizuho reissued a “buy” rating and issued a $103.00 target price on shares of Celgene in a research report on Tuesday. Nineteen equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $95.56.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. Celgene’s revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.05 earnings per share. On average, equities analysts expect that Celgene Co. will post 9.85 earnings per share for the current year.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What is meant by buying and selling pressure?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.